Smart Money Group LLC Purchases 745 Shares of Johnson & Johnson $JNJ

Smart Money Group LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.1% during the second quarter, Holdings Channel.com reports. The fund owned 7,432 shares of the company’s stock after buying an additional 745 shares during the period. Smart Money Group LLC’s holdings in Johnson & Johnson were worth $1,135,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nuveen LLC bought a new position in shares of Johnson & Johnson during the first quarter worth $1,369,188,000. Pacer Advisors Inc. grew its holdings in Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after buying an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after acquiring an additional 2,557,388 shares during the last quarter. Kingstone Capital Partners Texas LLC purchased a new stake in Johnson & Johnson during the second quarter valued at $401,420,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Johnson & Johnson by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 16,903,105 shares of the company’s stock worth $2,803,042,000 after buying an additional 2,129,612 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. Bank of America lifted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research report on Wednesday, October 15th. Royal Bank Of Canada restated an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research report on Friday, October 10th. Finally, The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Stock Up 0.5%

NYSE:JNJ opened at $186.92 on Friday. The company has a market cap of $450.33 billion, a price-to-earnings ratio of 18.04, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $184.06 and a 200-day simple moving average of $168.42.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.